Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics Inc (NTLA)
:NTLA
Total Valuation
Intellia Therapeutics has a market cap or net worth of $837.99M. The enterprise value is $862.11M.
Market Cap$837.99M
Enterprise Value$862.11M
Share Statistics
Intellia Therapeutics has 103,583,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,583,400
Owned by Insiders1.59%
Owned by Institutions37.96%
Financial Efficiency
Intellia Therapeutics’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -48.55%.
Return on Equity (ROE)-0.60
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-48.55%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee143.62K
Profits Per Employee-1.29M
Employee Count403
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Intellia Therapeutics is -2.22. Intellia Therapeutics’s PEG ratio is -0.54.
PE Ratio-2.22
PS Ratio0.00
PB Ratio0.95
Price to Fair Value1.32
Price to FCF-2.37
Price to Operating Cash Flow-2.37
PEG Ratio-0.54
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 57.88M and earned -519.02M in profits. Earnings per share was -5.25.
Revenue57.88M
Gross Profit47.59M
Operating Income-534.26M
Pretax Income-519.02M
Net Income-519.02M
EBITDA-508.74M
Earnings Per Share (EPS)-5.25
Cash Flow
In the last 12 months, operating cash flow was -348.88M and capital expenditures -5.78M, giving a free cash flow of -354.66M billion.
Operating Cash Flow-348.88M
Free Cash Flow-354.66M
Free Cash Flow per Share-3.42
Dividends & Yields
Intellia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.48
52-Week Price Change-65.25%
50-Day Moving Average7.93
200-Day Moving Average13.05
Relative Strength Index (RSI)49.10
Average Volume (3m)4.70M
Important Dates
Intellia Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Intellia Therapeutics as a current ratio of 5.77, with Debt / Equity ratio of 24.11%
Current Ratio5.77
Quick Ratio5.77
Debt to Market Cap0.02
Net Debt to EBITDA-0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Intellia Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Intellia Therapeutics EV to EBITDA ratio is -2.31, with an EV/FCF ratio of -3.31.
EV to Sales20.28
EV to EBITDA-2.31
EV to Free Cash Flow-3.31
EV to Operating Cash Flow-3.36
Balance Sheet
Intellia Therapeutics has $601.51M in cash and marketable securities with $210.20M in debt, giving a net cash position of -$391.32M billion.
Cash & Marketable Securities$601.51M
Total Debt$210.20M
Net Cash-$391.32M
Net Cash Per Share-$3.78
Tangible Book Value Per Share$8.82
Margins
Gross margin is 86.74%, with operating margin of -923.10%, and net profit margin of -896.77%.
Gross Margin86.74%
Operating Margin-923.10%
Pretax Margin-896.77%
Net Profit Margin-896.77%
EBITDA Margin-879.00%
EBIT Margin-923.10%
Analyst Forecast
The average price target for Intellia Therapeutics is $30.44, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.44
Price Target Upside276.27% Upside
Analyst ConsensusModerate Buy
Analyst Count21
Revenue Growth Forecast-13.37%
EPS Growth Forecast2.57%